SCHEMBL4572048

SCHEMBL4572048

Cc1cccc2c(=O)[nH][nH]c(=O)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
PARP1 P09874 6/20 0.47
ALOX5 P09917 1/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2A6 P11509 1/20 0.44
DAO P14920 1/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHEK1 O14757 1/20 0.40
TNKS O95271 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
TYMS P04818 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912556 0.78 PLK4 (0.53) ALDH1A1PARP1ALOX5CYP1A2DAO
SCHEMBL9669189 0.78 DAO (0.59) ALDH1A1PARP1ALOX5CYP1A2CYP2A6
SCHEMBL2230531 0.78 ALDH1A1 (0.53) ALDH1A1ALOX5DAOKDM4ELMNA
SCHEMBL4115828 0.76 ALDH1A1 (0.61) ALDH1A1ALOX5DAOKDM4ELMNA
SCHEMBL12286658 0.75 PARP1 (0.49) PARP1CYP1A2CYP2A6KDM4ESMN1; SMN2
SCHEMBL12440976 0.75 PARP1 (0.49) PARP1CYP1A2CYP2A6KDM4ECHEK1
SCHEMBL24619693 0.74 ALDH1A1 (0.59) ALDH1A1PARP1ALOX5DAOKDM4E
SCHEMBL10485055 0.74 DAO (0.64) ALDH1A1PARP1ALOX5CYP1A2CYP2A6
SCHEMBL3758295 0.74 ALDH1A1 (0.59) ALDH1A1PARP1ALOX5DAOKDM4E
SCHEMBL182680 0.74 ALDH1A1 (0.59) ALDH1A1PARP1ALOX5CYP1A2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4207112-A STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1980-06-10 US claimed
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2025-05-15 US disclosed
CN-119137113-A THR beta analogues and uses thereof 马德里加尔制药公司 2024-12-13 CN disclosed
WO-2023154842-A1 THR BETA ANALOGS AND USES THEREOF MADRIGAL PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
WO-2023154842-A1 THR BETA ANALOGS AND USES THEREOF MADRIGAL PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
US-RE49351-E1 Cytoprotective agent BIOGEN MA INC. (US) 2023-01-03 US disclosed
US-20220218664-A1 DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG SHOWA UNIVERSITY (JP) 2022-07-14 US disclosed
US-20210322381-A1 DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) 2021-10-21 US disclosed
EP-3186227-B1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS ELANCO TIERGESUNDHEIT AG (CH) 2021-03-24 EP disclosed
EP-3792251-A1 NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS Elanco Tiergesundheit AG (CH) 2021-03-17 EP disclosed
US-20090163465-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090149438-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-11 US disclosed
US-7521457-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-21 US disclosed
EP-2000540-A9 TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER Tokyo University of Agriculture and Technology TLO Co., Ltd. (JP) 2009-03-25 EP disclosed
EP-2000540-A2 TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER Tokyo University of Agriculture and Technology TLO Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20070184513-A1 Substrates for beta-lactamase and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-09 US disclosed
US-20070020715-A1 Novel fluorogenic substrates for beta-lactamase gene expression THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2007-01-25 US disclosed
US-7157575-B2 Substrates for β-lactamase and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-02 US disclosed
US-4207112-A STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1980-06-10 US disclosed
US-4076534-A Heat developable light-sensitive material FUJI PHOTO FILM CO., LTD. (JA) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210322381-A1 DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG PROC, FABP7, TIMP3 ALDH1A1 911/4885PARP1 3490/4885ALOX5 400/4885
US-20090163465-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP ALDH1A1 971/4885PARP1 125/4885ALOX5 3173/4885
US-20070020715-A1 Novel fluorogenic substrates for beta-lactamase gene expression CMBL, HRH3, TDO2 ALDH1A1 2530/4885PARP1 4615/4885ALOX5 2545/4885
US-20220218664-A1 DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG SLC5A2, SLC5A1, IAPP ALDH1A1 342/4885PARP1 4274/4885ALOX5 71/4885
US-20090149438-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP ALDH1A1 971/4885PARP1 125/4885ALOX5 3173/4885
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF THRB, THRA, TSHR ALDH1A1 2389/4885PARP1 4332/4885ALOX5 3971/4885
US-20070184513-A1 Substrates for beta-lactamase and uses thereof CMBL, DBH, NCEH1 ALDH1A1 1941/4885PARP1 4409/4885ALOX5 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.